XRAY crushed it: +17.1% WoW on the back of restructuring announcements and $1.1B in PE deal activity (Dental365's $440M acquisition, Specialty Dental Brands' $660M financing). HSIC +3.5%, NVST +0.3%, and ALGN flat at $190.10 despite YTD gains of +21.8% and +30.3% respectively, suggest the sector's momentum is concentrated in consolidation plays and distressed operators. The filing surge (10-K/8-K across XRAY, HSIC, ALGN) signals year-end cleanup before Q1 earnings. For DSO operators: PE valuations are inflated by cheap capital and deal flow, but regulatory friction is mounting—Massachusetts tightened M&A review, and Aspen Dental faces yet another investigation for deceptive practices. The message is clear: acquisition multiples will compress if PE appetite cools or state-level scrutiny intensifies. Practice owners should lock in exit timing now.

ELV tanked -6.7% WoW after filing an 8-K citing executive departures and strategic shifts (Item 5.02 suggests C-suite turnover). Meanwhile, CVS (+4.2%), CNC (+3.8%), CI (+3.4%), and MOH (+2.0%) eked out gains, but this is a hollow rally—all are still underwater YTD except CVS (+0.5%). The real story is margin compression: CMS closed the $600M Medicaid tax loophole, halted Minnesota's $259M Medicaid draw citing fraud, and is demanding full prior auth automation within double-digit months. HUM's -28.0% YTD collapse reflects the death spiral of MA profitability—forced disenrollments are skyrocketing from 1% to 10% by 2026, destabilizing patient panels. For payer executives: this is a tightening cycle, not a loosening one. Medicaid rates will compress as states enforce cost-share requirements, and MA margins are imploding faster than volume gains can offset. Stock support only comes if earnings beats materially exceed forward guidance.

ACHC exploded +39.6% WoW to $23.44 on the week, signaling massive reversal of short positioning or institutional accumulation ahead of earnings. UHS (-10.6%) is the week's worst performer, dragging down the sector despite THC's +4.1% rebound and DVA's +3.7% strength. HCA (-0.5%) is sideways, while CYH (-2.8%) and SEM (-0.3%) are deteriorating. The divergence is telling: behavioral health (ACHC) is winning as Medicare Advantage churn drives higher acuity admissions, while general acute care (UHS, HCA) faces patient disruption. CMS's fraud crackdown and Medicare Advantage disenrollment wave are reshaping the patient mix faster than hospital systems can adapt. For hospital CFOs: revenue cycle optimization is no longer optional—MA disenrollments are immediate cash bleed, workforce attrition (nurses fleeing to Canada) is accelerating, and compliance overhead is ballooning. The spread between behavioral health and acute care will continue to widen until general hospital systems right-size capacity.

AGL ripped +34.5% WoW after Q4 earnings beat ($1.57B revenue vs. $1.46B consensus), but Q1 2026 guidance disappointed ($1.35-1.39B vs. $1.57B expectations). The stock's volatility and positive weekly action suggest short covering and institutional rotation into AI-enabled primary care platforms ahead of full-year margin improvement bets. TDOC rebounded +11.0% as Medicaid subsidy expiration headwinds plateau, while HIMS cratered -7.1% YTD (-56.5%) and PGNY (-15.7% WoW) face structural headwinds from ACA subsidy collapse and payer margin pressure. ALHC (-6.7%) and GDRX (-24.3% WoW) are value traps masking deteriorating unit economics. For primary care and telehealth operators: the margin compression from payer rate cuts is real and persistent. AGL's recovery signals that scale, vertical integration, and AI-driven cost reduction can offset macro headwinds, but pure-play telehealth and fertility benefit platforms (PGNY) have no path to profitability without major restructuring or strategic M&A.